

DAFTAR PUSTAKA

- Adams, L.A., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G.W. & Jeffrey, G.P. 2005. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clin Chem*, 51(10): 1867–1873.
- Ala, A., Dhillon, A. & Hodgson, H.J. 2003. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. *IJEP*, 84(1): 1–16.
- Amirudin, R. 2012. Fibrosis hati. In Sulaiman, Akbar, Lesmana, & Noer, eds. *Buku Ajar Ilmu Penyakit Hati*. Jakarta : CV Sagung Seto: pp: 341-345.
- Angeli, P. & Gines, P. 2012. Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. *J Hepatol*, 57(5): 1135–1140.
- Anonim. 2013. *Human IL-13 (Interleukin 13) ELISA Kit*.
- Aoudjehane, L., Briand, V., Beauverger, P., Janiak, P., Calmus, Y. & Conti, F. 2013. *IL-4 and IL-13 Over-Expression In Severe Recurrent Hepatitis C After Liver Transplantation*. Elsevier B.V. and European Association for the Study of the Liver.
- Aubé, C., Oberti, F., Korali, N., Namour, M.-A., Loisel, D., Tanguy, J.-Y., Valsesia, E., Pilette, C., Rousselet, M.C., Bedossa, P., Rifflet, H., Maïga, M.Y., Penneau-Fontbonne, D., Caron, C. & Calès, P. 1999. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. *J Hepatol*, 30(3): 472–478.
- Bataller, R. & Brenner, D. 2009. Hepatic fibrosis. In *Arias, I.M (ed), The liver: Biology and pathobiology*. 5 th ed. Willey Blackwell, UK: pp 433-452.
- Bernardi, M., Gitto, S. & Biselli, M. 2011. The MELD score in patients awaiting liver transplant: Strengths and weaknesses. *J Hepatol*, 54(6): 1297–1306.
- Bonacchi, A., Petrai, I., Franco, R.M.S.D.E., Lazzeri, E., Annunziato, F., Efsen, E.V.A., Cosmi, L., Romagnani, P., Milani, S., Failli, P., Batignani, G., Liotta, F., Laffi, G., Pinzani, M., Gentilini, P. & Marra, F. 2003. The Chemokine CCL21 Modulates Lymphocyte Recruitment and Fibrosis in Chronic Hepatitis C. *Gastroenterology*, 125: 1060–1076.
- Borden, L.M. 2009. Understanding Correlation. In *University of Arizona Military Reach*. Arizona: 1–5.
- Buey, L.G., Mateos F, G. & Moreno-Otero, R. 2012. Cirrosis hepática. *medicine*, 11: 625–33.
- But, D.Y.K., Lai, C.L. & Yuen, M.F. 2008. Natural history of hepatitis-related hepatocellular carcinoma. *WJG*, 14(11): 1652–1656.
- Cadranel, J.F., Rufat, P. & Degos, F. 2000. Practices of liver biopsy in France: Results of a prospective nationwide survey. *Hepatology*, 32(3): 477–481.
- Cárdenas, A. & Ginès, P. 2009. A Patient With Cirrhosis and Increasing Creatinine Level: What Is It and What to Do? *CGH*, 7(12): 1287–1291.
- Chiaromonte, M.G., Cheever, A.W., Malley, J.D., Donaldson, D.D. & Wynn, T.A. 2001. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. *Hepatology*, 34(2): 273–282.
- Coombes, J.M. & Trotter, J.F. 2005. Development of the allocation system for

- deceased donor liver transplantation. *Clin Med Res*, 3(2): 87–92.
- D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *J Hepatol*, 44(1): 217–231.
- Dahlan, S. 2011. *Statistika Untuk Kedokteran dan Kesehatan*. 5th ed. Jakarta: Salemba Medika.
- Dancygier, H. 2010a. *Clinical Hepatology*. Berlin, Heidelberg: Springer Berlin Heidelberg. pp 949-1015. <http://link.springer.com/10.1007/978-3-642-04519-6>.
- Dancygier, H. 2010b. *Clinical Hepatology*. Berlin, Heidelberg: Springer Berlin Heidelberg. pp15-47. <http://link.springer.com/10.1007/978-3-540-93842-2>.
- Deng, Y., Xie, M., Xie, L., Wang, J., Li, T., He, Y., Li, R., Li, S. & Qin, X. 2015. Association between Polymorphism of the Interleukin-13 Gene and Susceptibility to Hepatocellular Carcinoma in the Chinese Population W. B. Coleman, ed. *PLOS ONE*, 10(2): e0116682.
- Dondeti, M.F., El-Maadawy, E.A. & Talaat, R.M. 2016. Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms. *WJG*, 22(30): 6800–6816.
- Dooley, J.S., Lok, A.S.F., Burroughs, A.K. & Heathcote, E.J. eds. 2011. *Sherlock’s Diseases of the Liver and Biliary System*. 12th ed. Oxford, UK: Wiley-Blackwell. pp 546-567. <http://doi.wiley.com/10.1002/9781444341294>.
- Dowman, J.K., Tomlinson, J.W. & Newsome, P.N. 2011. Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharm Ther*, 33(5): 525–540.
- Droge, W. 2002. Free Radicals in the Physiological Control of Cell Function. *Physiol Rev*, 82: 47–95.
- Dultz, G., Seelhof, M., Herrmann, E., Welker, M.W., Friedrich-Rust, M., Teuber, G., Kronenberger, B., von Wagner, M., Vermehren, J., Sarrazin, C., Zeuzem, S. & Hofmann, W.P. 2013. Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. *PLoS ONE*, 8(8): 1–6.
- Fattovich, G., Bortolotti, F. & Donato, F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. *J Hepatol*, 48(2): 335–352.
- Flores-Rendon, A.R., Gonzalez-Gonzalez, J.A., Garcia-Compean, D., Maldonado-Garza, H.J. & Garza-Galindo, A. 2008. Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. *Ann Hepatol*, 7(July): 230–234.
- Friedman, S.L. 2003. Liver fibrosis – from bench to bedside. *J Hepatol*, 38(81): S38–S53.
- Friedman, S.L. 2008. Mechanisms of hepatic fibrogenesis. *Gastroenterology*, 134(6): 1655–1669.
- Gheorghe, L., Iacob, S., Iacob, R., Gheorghe, C. & Popescu, I. 2007. Variation of the MELD score as a predictor of death on the waiting list for liver transplantation. *J Gastrointestin liver dis*, 16(3): 267–272.

- Giannini, E.G., Testa, R. & Savarino, V. 2005. Liver enzyme alteration: A guide for clinicians. *CMAJ*, 172(3): 367–379.
- González-Reimers, E., Santolaria-Fernández, F., Medina-García, J. a, González-Pérez, J.M., de la Vega-Prieto, M.J., Medina-Vega, L., Martín-González, C. & Durán-Castellón, M.C. 2012. TH-1 and TH-2 cytokines in stable chronic alcoholics. *Alcohol and alcoholism*, 47(4): 390–6.
- Guyton, A. 2007. *Buku Ajar Fisiologi Kedokteran*. 2nd ed. EGC. Jakarta.
- Hammerich, L. 2014. Interleukins in chronic liver disease : lessons learned from experimental mouse models. *Clin Exp Gastroenterol*, 7: 297–306.
- Hershey, G.K.K. 2003. IL-13 receptors and signaling pathways: An evolving web. *J Allergy Clin Immunol*, 111(4): 677–690.
- Kanto, T. & Hayashi, N. 2007. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. *Hepatol Res*, 37: S319–S326.
- Karina. 2007. *Faktor risiko kematian penderita sirosis hati di RSUP dr. Kariadi Semarang tahun 2002 – 2006*. Jurnal Media Medika Muda. <http://eprints.undip.ac.id/view/divisions/sch=5Fmed/2007>.
- Kaviratne, M., Hesse, M., Leusink, M., Cheever, A.W., Davies, S.J., McKerrow, J.H., Wakefield, L.M., Letterio, J.J. & Wynn, T.A. 2004. IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF- Independent. *J Immunol*, 173(6): 4020–4029.
- Klavan, H.L. & Fortune, B.E. 2016. Elevated Creatinine in a Patient With Cirrhosis. *Clin Liver Dis*, 7(3): 48–52.
- Kong, X., Horiguchi, N., Mori, M. & Gao, B. 2012. Cytokines and STATs in liver fibrosis. *Frontiers in Physiology*, 3(69): 1–7.
- Konstantinou, D. & Deutsch, M. 2015. The spectrum of HBV / HCV coinfection : epidemiology , clinical characteristics , viral interactions and management. *Ann Gastroenterol*, 28(2): 221–228.
- Kraja, B., Sina, M., Mone, I., Pupuleku, F., Babameto, A., Prifti, S. & Burazeri, G. 2012. Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. *Hindawi*, 2012: 1–5.
- Kumar, R., Krishnamoorthy, T.L., Tan, H.K., Lui, H.F. & Chow, W.C. 2015. Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. *Gastroenterol Rep*, 3(2): 122–127.
- Kusumobroto, H.O. 2007. *Sirosis Hati dalam Buku Ajar Ilmu Penyakit Hati*. 1st ed. Jakarta: Jaya Abadi.
- de Lalla, C., Galli, G., Aldrighetti, L., Romeo, R., Mariani, M., Monno, A., Nuti, S., Colombo, M., Callea, F., Porcelli, S.A., Panina-Bordignon, P., Abrignani, S., Casorati, G. & Dellabona, P. 2004. Production of Profibrotic Cytokines by Invariant NKT Cells Characterizes Cirrhosis Progression in Chronic Viral Hepatitis. *J Immunol*, 173(2): 1417–1425.
- Lee, J.W. 2009. Renal dysfunction in patients with chronic liver disease. *Electrolyte Blood Press*, 7(2): 42–50.
- Liu, Y., Munker, S., Müllenbach, R. & Weng, H.L. 2012. IL-13 signaling in liver

- fibrogenesis. *Frontiers in Immunology*, 3: 1–7.
- Low, G., Alexander, G.J.M. & Lomas, D.J. 2015. Hepatorenal Syndrome : Aetiology , Diagnosis , and Treatment. *Hindawi*: 1–12.
- Ming, F., Yin, X., Ma, X., Guo, X.-D., Jin, B. & Li, H. 2013. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. *Biomed Rep*, 1(2): 265–268.
- Møller, S., Henriksen, J.H. & Bendtsen, F. 2014. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. *WJG*, 20(42): 15499–15517.
- Moore, C.M., George, M., Lateef, O. & Van Thiel, D.H. 2012. The MELD score: Limitations and consequences. *WSEAS*, 9(2): 55–65.
- Morimoto, N., Okada, K. & Okita, Y. 2013. The model for end-stage liver disease (MELD) predicts early and late outcomes of cardiovascular operations in patients with liver cirrhosis. *Ann Thorac Surg*, 96(5): 1672–1678.
- Muciño-bermejo, J., Carrillo-esper, R., Uribe, M. & Méndez-sánchez, N. 2013. Coagulation abnormalities in the cirrhotic patient. *Ann Hepatol*, 12(5): 713–724.
- Muir, A.J. 2015. Understanding the Complexities of Cirrhosis. *ClinTher*, 37(8): 1822–1836.
- Mukherjee, P.S., Vishnubhatla, S. & Amarpurkar, D.N. 2017. Etiology and mode of presentation of chronic liver diseases in India : A multi centric study. *PLoS ONE*, 12(10): 1–13.
- Muljono, D.H. 2017. Epidemiology of Hepatitis b and c in Republic of Indonesia. *J Hepato-Gastroenterol*, 7(1): 55–59.
- Ng, C.K., Chan, M.H., Tai, M.H. & Lam, C.W. 2007. Hepatorenal syndrome. *Clin Biochem Rev Vol*, 28(2): 11–17.
- Nosseir, N.M., Mansour, H.H. & Alkady, M.M. 2009. Interleukin-6, Interleukin-8, Interleukin-13 and Interferon- in Hepatocellular Carcinoma. *J. Rad. Res. Appl. Sci*, 2(3): 577–592.
- Nurdjanah, S. 2009. Sirosis hati. In S. A.W., Sudoyo, B., Setiyohadi, I., Alwi, M., Simadibrata, S., ed. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Interna Publishing: 668–673.
- Nusrat, S., Khan, M.S., Fazili, J. & Madhoun, M.F. 2014. Cirrhosis and its complications: Evidence based treatment. *WJG*, 20(18): 5442–5460.
- Ohkubo, A. 1994. Bilirubin metabolism in liver cirrhosis. *J clin med*, 52(1): 138–44.
- Papadopoulos, V., Filippou, D., Manolis, E. & Mimidis, K. 2007. Haemostasis impairment in patients with obstructive jaundice. *J Gastrointestin liver dis*, 16(2): 177–186.
- Petruzzello, A., Marigliano, S., Loquercio, G., Cozzolino, A. & Cacciapuoti, C. 2016. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *WJG*, 22(34): 7824–7840.
- Pleli, T., Martin, D., Kronenberger, B., Brunner, F., Köberle, V., Grammatikos, G., Farnik, H., Martinez, Y., Finkelmeier, F., Labocha, S., Ferreirós, N., Zeuzem, S., Piiper, A. & Waidmann, O. 2014. Serum autotaxin is a parameter for the

- severity of liver cirrhosis and overall survival in patients with liver cirrhosis - A prospective cohort study. *PLoS ONE*, 9(7): 1–9.
- Rognant, N. & Lemoine, S. 2014. Evaluation of renal function in patients with cirrhosis: Where are we now? *WJG*, 20(10): 2533–2541.
- Ruíz-del-Árbol, L. 2015. Cirrhotic cardiomyopathy. *WJG*, 21(41): 11502–11521.
- S. Paul Starr, D.R. 2011. Cirrhosis: Diagnosis, Management, and Prevention. *Am Fam Physician*, 84(12): 1353–1359.
- Samonakis, D.N., Koulentaki, M., Coucoutsis, C., Augoustaki, A., Baritaki, C., Digenakis, E., Papiamoni, N., Fragaki, M., Matrella, E., Tzardi, M. & Kouroumalis, E.A. 2014. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. *WJH*, 6(7): 504–512.
- Sastroasmoro & Ismael, S. 2014. *Dasar-dasar Metodologi Penelitian Klinis*.
- Schuppan, D. 2015. Liver fibrosis: Common mechanisms and antifibrotic therapies. *Clin Res Hepatol Gastroenterol*, 39: S51–S59.
- Schuppan, D. & Afdhal, N.H. 2008. Liver Cirrhosis. *NIH*, 371(9615): 838–851.
- Shaikh, P.Z. 2011. Cytokines & their physiologic and pharmacologic functions in inflammation. *Int. J. of Pharm. & Life Sci. (IJPLS)*, 2(11): 1247–1263.
- Shaikh, S., Ghani, H., Memon, S., Baloch, G.H., Jaffery, M. & Shaikh, K. 2010. MELD era: Is this time to replace the original child-pugh score in patients with decompensated cirrhosis of liver. *JCPSP*, 20(7): 432–435.
- Shimamura, T., Fujisawa, T., Husain, S.R., Kioi, M., Nakajima, A. & Puri, R.K. 2008. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. *J Immunol*, 181(7): 4656–65.
- Starr, S.P. & Raines, D. 2011. Cirrhosis: Diagnosis, management, and prevention. *Am Fam Physician*, 84(12): 1353–1359.
- Sugimoto, R., Enjoji, M., Nakamuta, M., Ohta, S., Kohjima, M., Fukushima, M., Kuniyoshi, M., Arimura, E., Morizono, S., Kotoh, K. & Nawata, H. 2005. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. *Liver International*, 25(2): 420–428.
- Sugiyono. 2017. *Metode Penelitian Kuantitatif, Kualitatif R & D*. Bandung: Alfabeta. <https://massugiyantojambi.wordpress.com/2011/04/15/teori-motivasi/>.
- Thapa, B. & Walia, A. 2007. Liver Function Tests and their Interpretation. *Indian J Pediatr*, 74(7): 663–671.
- Wait, S., Kell, E., Hamid, S., Muljono, D.H., Sollano, J., Mohamed, R., Shah, S., Mamun-Al-Mahtab, Abbas, Z., Johnston, J., Tanwandee, T. & Wallace, J. 2016. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. *Lancet Gastro Hep*, 1(3): 248–255.
- Wang, X., Chowdhury, J.R. & Chowdhury, N.R. 2006. Bilirubin metabolism: Applied physiology. *Elsevier*, 16(1): 70–74.
- Weng, H.L., Liu, Y., Chen, J.L., Huang, T., Xu, L.J., Godoy, P., Hu, J.H., Zhou, C., Stickel, F., Marx, A., Bohle, R.M., Zimmer, V., Lammert, F., Mueller, S., Gigou, M., Samuel, D., Mertens, P.R., Singer, M. V., Seitz, H.K. & Dooley, S. 2009. The etiology of liver damage imparts cytokines transforming growth factor 1 or interleukin-13 as driving forces in fibrogenesis. *Hepatology*,

50(1): 230–243.

WHO. 2017. *Global hepatitis report, 2017*.

Wynn, T.A. 2008. Cellular and molecular mechanisms of fibrosis. *J Pathol*, 214(2): 199–210.

Wynn, T.A. 2004. Fibrotic Disease And The Th 1/Th 2 Paradigm. *Nat Rev Immunol*, 4(8): 583–594.

Ydreborg, M. 2013. On the assessment and impact of liver fibrosis in patients with chronic Hepatitis C. : 1–83.